US Patent

US12576032 — Liquid clonidine extended release composition

Method of Use · Assigned to Tris Pharma Inc · Expires 2041-07-28 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a liquid clonidine extended release composition that provides a 24-hour release profile after a single dose administration.

USPTO Abstract

An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile. Dosage units may also provide an immediate release component.

Drugs covered by this patent

clonidine-hydrochloride (CLONIDINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2357`	—	clonidine-hydrochloride

Patent Metadata

Patent number: US12576032
Jurisdiction: US
Classification: Method of Use
Expires: 2041-07-28
Drug substance claim: No
Drug product claim: No
Assignee: Tris Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.